🏛️ Verified NIH Record • Updated 2026-08-20
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors (NCT05765851)
A Phase 1, 2-Part, Multicenter, First-In-Human Dose-Escalation and Dose-Expansion Study of DS-1103a Combination Therapy in Subjects With Advanced Solid Tumors
🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Daiichi Sankyo
🩺 Plain-English Summary (8th-Grade Level)
This study will evaluate the safety and efficacy of DS-1103a combination therapy in participants with advanced solid tumors.
Who can join: Review the eligibility criteria below.
Location: Florida Cancer Specialists — Sarasota, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- Florida Cancer Specialists — Sarasota, Florida
- Lifespan Cancer Institute — Providence, Rhode Island
- University of Utah — Salt Lake City, Utah
- NEXT Oncology — Fairfax, Virginia
- Princess Margaret Cancer Centre, University Health Network — Toronto,
- Oncopole - Institut Claudius Regaud — Toulouse, Haute Garonne
- Centre Léon Bérard — Lyon, Rhone
- Centre Léon Bérard — Lyon,
- Oncopole - Institut Claudius Regaud — Toulouse,
- The Cancer Institute Hospital Of JFCR — Tokyo,
- Hospital Universitari Vall d'Hebron — Barcelona,
📞 Contact the Study Coordinator
Phone: (908) 992-6400
Email: CTRinfo@dsi.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumor
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
- A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
- QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
- A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
- First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
- A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas
Explore by condition: All Advanced Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.